What is Pervasive Arousal Withdrawal Syndrome, also known as Post-Acute Withdrawal Syndrome (PAWS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Pervasive arousal withdrawal syndrome, also known as protracted withdrawal, should be preempted and treated with liberal use of adjuvant agents along with adequate clinician time and support, as it can cause dysphoria, irritability, insomnia, anhedonia, or a vague sense of being unwell months after opioid elimination. When managing patients with opioid use disorder, it is essential to consider the potential for protracted withdrawal symptoms, which can be challenging to differentiate from chronic pain symptoms 1. The symptoms of protracted withdrawal can be severe and debilitating, affecting the patient's quality of life and increasing the risk of relapse.

Key Considerations

  • Protracted withdrawal symptoms can occur months after opioid elimination and may include dysphoria, irritability, insomnia, anhedonia, or a vague sense of being unwell 1
  • These symptoms can be challenging to differentiate from chronic pain symptoms and may reflect an unmasking of the original chronic pain problem
  • Preempting and treating protracted withdrawal symptoms with adjuvant agents and adequate clinician time and support is crucial to improving patient outcomes 1
  • Clinicians should convey to patients that many individuals receiving long-term opioid therapy (LTOT) actually feel and function better following opioid tapering 1

Management Strategies

  • Liberal use of adjuvant agents to manage protracted withdrawal symptoms
  • Adequate clinician time and support to address patient concerns and provide guidance
  • Gradual opioid tapering to minimize the risk of acute withdrawal symptoms 1
  • Consideration of buprenorphine initiation in patients taking opioids for pain, with careful monitoring and dose adjustment as needed 1

From the FDA Drug Label

Pervasive arousal withdrawal syndrome is not explicitly mentioned in the provided drug labels. However, the labels do describe protracted withdrawal syndrome associated with benzodiazepines, which is characterized by:

  • Anxiety
  • Cognitive impairment
  • Depression
  • Insomnia
  • Formication
  • Motor symptoms (e.g., weakness, tremor, muscle twitches)
  • Paresthesia
  • Tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months 2 3.

The key points are:

  • Protracted withdrawal syndrome is a potential risk of benzodiazepine use
  • Symptoms can persist for an extended period
  • Gradual tapering is recommended to reduce the risk of withdrawal reactions. It is essential to note that pervasive arousal withdrawal syndrome is not directly mentioned in the provided labels, and therefore, no conclusion can be drawn about this specific condition.

From the Research

Definition and Characteristics

  • Pervasive arousal withdrawal syndrome (PAWS) is a rare mental health disorder that commonly affects children and young people, characterized by dramatic social withdrawal and determined refusal to walk, talk, eat, drink, or care for themselves in any way for several months 4.
  • PAWS is often associated with pervasive refusal syndrome (PRS), and in extreme cases, young people may be unable to perform activities of daily living and rely on adults for physical and emotional support 4.

Relationship to Benzodiazepine Withdrawal

  • While PAWS is not directly related to benzodiazepine withdrawal, the symptoms of benzodiazepine withdrawal syndrome, such as sleep disturbance, irritability, and increased tension and anxiety, may be similar to those experienced by individuals with PAWS [(5,6)].
  • Benzodiazepine withdrawal syndrome is typically characterized by a range of symptoms, including rebound anxiety and insomnia, and can occur after prolonged treatment with therapeutic doses 6.

Conceptualization and Renaming

  • PAWS has been conceptualized in various ways, including as a form of post-traumatic stress disorder, learnt helplessness, or depressive devitalisation 7.
  • A neurobiological explanatory model based on autonomic system hyper-arousal has been proposed, and a new name for the condition has been suggested to reflect a more sophisticated understanding of the disorder 7.

Clinical Implications

  • It is essential for healthcare professionals to be aware of PAWS and have some insight into the most helpful approaches, including validating the experiences of young people and providing emotional support 4.
  • Staff should be able to talk and reflect on their feelings to understand and manage their responses to young people with PAWS 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Staff perspectives on two rare mental health disorders.

Nursing children and young people, 2016

Research

Benzodiazepine withdrawal syndrome: a literature review and evaluation.

The American journal of drug and alcohol abuse, 1982

Research

The benzodiazepine withdrawal syndrome.

Addiction (Abingdon, England), 1994

Related Questions

When do peak withdrawal symptoms from benzodiazepines (BZDs), such as Xanax (alprazolam) and Valium (diazepam), typically occur?
What is the management of Pervasive Arousal Withdrawal Syndrome, also known as Post-Acute Withdrawal Syndrome (PAWS)?
What are the potential consequences of abrupt cessation of benzodiazepines (Benzodiazepines), including increased COWS (Clinical Opiate Withdrawal Scale) score, vomiting, diarrhea, rebound sympathetic nervous system (SMS) activity, or clinical depression?
Can a patient taking Brixadi (buprenorphine) take Gabapentin to protect against seizures after an Ativan (lorazepam) taper?
What are the consequences of abrupt cessation of benzodiazepines (BZD)?
What is the interaction between lithium and sodium (Na) chloride (salt)?
What is the diagnosis and treatment for neurogenic claudication (intermittent neurogenic claudication), a condition characterized by intermittent leg pain and weakness due to spinal stenosis or lumbar (lower back) spinal canal narrowing?
Is the dose of Levoxyl (levothyroxine) 75 micrograms still appropriate for this patient with hypothyroidism and a history of thyroid cancer, given a Thyroid-Stimulating Hormone (TSH) level of 0.113, indicating hypothyroidism is over-treated?
Is Dakin's (sodium hypochlorite) solution soaked gauze or Vashe (povidone-iodine) soaked gauze more effective for packing a sacral wound?
What is a dysphagia (difficulty swallowing) lesion?
What is the diagnosis for a 25-year-old patient presenting with epigastric pain, nausea, and vomiting, which worsen with food intake?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.